Quantum BioPharma - Class B opened at $1.94, in line with its previous close of $1.94. In the last trading session, the stock traded between $1.71 and $1.94. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Quantum BioPharma - Class B is now worth
$ 40.98
Resulting in a loss of
$ 59.02 (59.02%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.19 (-9.79%)
Day High
$1.94
Day Low
$1.71
Day Open
$1.94
Prev Close
$1.94
Volume
2,70,304
1W Return
-20.60%
1M Return
-37.97%
3M Return
-50.75%
6M Return
-65.42%
1Y Return
-79.69%
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
2.95
PEG Ratio
-
ROE
-433.27%
ROCE
-448.50%
EPS (TTM)
$-0.43
1 Week
-20.60%
1 Month
-37.97%
3 Months
-50.75%
6 Months
-65.42%
9 Months
-54.55%
Quantum BioPharma lifts voting control to 68% via C$80.86 placement
Quantum BioPharma closed a private placement raising C$80.86. Insider voting power increased from 57.01% to 68.22%. CEO and director entities acquired all 26 new Class A shares.
YesterdayQuantum BioPharma signs CRO contract for Phase 2 MS trial
Quantum BioPharma signed a Study Start-Up Agreement with Thermo Fisher Scientific for its Phase 2 Lucid-MS trial. The trial will evaluate Lucid-MS in patients with progressive forms of multiple sclerosis following FDA clearance. Lucid-MS targets protein arginine deiminase 2 to inhibit demyelination, showing promise in preclinical models. The global multiple sclerosis therapeutic market is projected to exceed $38 billion by 2030.
1mo agoQuantum BioPharma secures FDA clearance for Phase 2 MS trial
Quantum BioPharma secures FDA IND clearance for Lucid-MS Phase 2 trial. Study will be randomized, double-blind, and placebo-controlled. IND submission comprised approximately 15,000 pages of data. Company retains 19.84% stake in Unbuzzd Wellness Inc.
1mo agoQuantum BioPharma seeks CSE delisting, retains Nasdaq listing
Quantum BioPharma applies for voluntary delisting from CSE. Nasdaq, Frankfurt, and Upstream listings remain intact. Company cites low CSE trading volume and high costs. Class B shares will continue trading as QNTM on Nasdaq. Canadian shareholders must verify broker account compatibility.
2mo agoQuantum BioPharma grants 572,500 stock options at C$4.80
Quantum BioPharma granted 572,500 stock options at an exercise price of C$4.80. 172,500 options vested immediately while 400,000 are subject to performance conditions. Options expire on August 20, 2031 under the 2023 omnibus equity incentive plan. Company retains 19.48% stake in Unbuzzd Wellness Inc. with tiered royalty structure.
2mo agoQuantum BioPharma secures FDA IND clearance for Lucid-MS Phase 2 trial
Quantum BioPharma Ltd. (NASDAQ: QNTM) reported Q2 2026 operating expenses of $2.29 million, a 53% YoY decline, boosting cash reserves to $9.5 million. The FDA approved the IND for Lucid-MS on August 10, 2026, enabling Phase 2 trials for progressive multiple sclerosis. Management projects sufficient liquidity through October 2027.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Quantum BioPharma - Class B is now worth
$ 40.98
Resulting in a loss of
$ 59.02 (59.02%)
Note: Past profits do not guarantee future returns.
